Millennium Management
AKBA icon

Millennium Management’s Akebia Therapeutics AKBA Stock Holding History

Millennium Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-700,000
Closed -$503K – 6918
2022
Q1 		$503K Buy
+700,000
New +$1.5M ﹤0.01% 5117
2021
Q1 		– Sell
-600,000
Closed -$1.68M – 5855
2020
Q4 		$1.68M Buy
+600,000
New +$1.75M ﹤0.01% 3381

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Millennium Management's AKBA Position: Q1 2026 in Review

Millennium Management increased its Akebia Therapeutics (AKBA) stake by 44% in Q1 2026, buying an estimated $1M and bringing the position to 2,384,713 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3381.

Millennium Management first reported a position in AKBA in Q3 2014 and has held it in 44 quarters since. The position peaked at $15.4M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Millennium Management held 2,384,713 shares of Akebia Therapeutics worth $3.31M as of Q1 2026.
  • Millennium Management bought 731,244 Akebia Therapeutics shares in Q1 2026, an estimated $1M.
  • Akebia Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3381 holding.
  • Millennium Management first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 44 quarters since.
  • Millennium Management's Akebia Therapeutics position peaked at $15.4M in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.